<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37606034</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Mast cell activation may contribute to adverse health transitions in COVID-19 patients with frailty.</ArticleTitle><Pagination><StartPage>2251589</StartPage><MedlinePgn>2251589</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2251589</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2023.2251589</ELocationID><Abstract><AbstractText>A prominent aspect of the post-coronavirus disease-2019 (post-COVID-19) era is long-COVID. Therefore, precise patient classification and exploration of the corresponding factors affecting long-COVID are crucial for tailored treatment strategies. Frailty is a common age-related clinical syndrome characterized by deteriorated physiological functions of multiple organ systems, which increases susceptibility to stressors. Herein, we performed an inclusion and exclusion analysis (definite COVID-19 infection diagnosis, clear underlying disease information, &#x2265;60 years old, and repeated sampling of clinical cases) of 10,613 blood samples and identified frailty cases for further investigation. RNA-Seq data were used for differential gene expression and functional and pathway analyses. The results revealed that patients with frailty were more prone to poor health conversions and more sequelae, and the blood transcriptome had obvious disturbances in pathways associated with immune regulation, metabolism, and stress response. These adverse health transitions were significantly associated with mast cell activation. Additionally, NCAPG, MCM10, and CDC25C were identified as hub genes in the peripheral blood differential gene cluster, which could be used as diagnostic markers of poor health conversion. Our results indicate that healthcare measures should be prioritized to mitigate adverse health outcomes in this vulnerable patient group, COVID-19 patients with frailty, in post-COVID era.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiangqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Gongli Hospital, Naval Medical University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chaobao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Clinical Geriatric Medicine; Department of Geriatric Medicine, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Zhijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Clinical Geriatric Medicine; Department of Geriatric Medicine, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073496" MajorTopicYN="Y">Frailty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019456" MajorTopicYN="N">Health Transition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">etiology</Keyword><Keyword MajorTopicYN="N">frailty</Keyword><Keyword MajorTopicYN="N">mast cell</Keyword><Keyword MajorTopicYN="N">transitions</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37606034</ArticleId><ArticleId IdType="pmc">PMC10469413</ArticleId><ArticleId IdType="doi">10.1080/22221751.2023.2251589</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, et al. . Pathophysiology of Post-COVID syndromes: a new perspective. Virol J. 2022;19(1):158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Jingna Hua XS, Wu Q, Li L, et al. . Analysis of the quality of life in patients with severe acute respiratory syndrome for 10 years. Tianjin Med J. 2016;44(10):1247&#x2013;1250.</Citation></Reference><Reference><Citation>Nurek M, Rayner C, Freyer A, et al. . Delphi p: recommendations for the recognition, diagnosis, and management of long COVID: A Delphi study. Br J Gen Pract. 2021;71(712):e815&#x2013;e825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510689</ArticleId><ArticleId IdType="pubmed">34607799</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RC, Simons NW, Wilkins L, et al. . Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nat Med. 2023;29(1):236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873574</ArticleId><ArticleId IdType="pubmed">36482101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaobao Z, Hongzhi W, Zilu W, et al. . Collective and individual assessment of the risk of death from COVID-19 for the elderly, 2020&#x2013;2022. China CDC Weekly. 2023;5(18):407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10184470</ArticleId><ArticleId IdType="pubmed">37197177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt J, Carter B, Vilches-Moraga A, et al. . The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020;5(8):e444&#x2013;e451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326416</ArticleId><ArticleId IdType="pubmed">32619408</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi LU, Aliberti MJR, Dias MB, et al. . Twelve months and counting: following clinical outcomes in critical COVID-19 survivors. Ann Am Thorac Soc. 2023;20(2):289&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9989854</ArticleId><ArticleId IdType="pubmed">36179057</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara T, Saida K, Tanaka S, et al. . Factors for the change in frailty status during the COVID-19 pandemic: a prospective cohort study over six- and 12-month periods in Japan. Geriatr Nurs. 2022;48:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436893</ArticleId><ArticleId IdType="pubmed">36155309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebremeskel S, Schanin J, Coyle KM, et al. . Mast cell and eosinophil activation Are associated With COVID-19 and TLR-mediated viral inflammation: implications for an Anti-Siglec-8 antibody. Front Immunol. 2021;12:650331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988091</ArticleId><ArticleId IdType="pubmed">33777047</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti MP, Weller E, Alvarez-Twose I, et al. . COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract. 2021;9(5):2083&#x2013;2086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899934</ArticleId><ArticleId IdType="pubmed">33631409</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun S, Storan A, Myers B.. Mast cell activation syndrome and the link with long COVID. Br J Hosp Med (Lond). 2022;83(7):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">35938771</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ.. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, et al. . Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021;112:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, et al. . Youngblood BA: mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2022;77(4):1288&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone RW, Tisdall P, Fremont-Smith P, et al. . COVID-19: famotidine, histamine, mast cells, and mechanisms. Front Pharmacol. 2021;12:633680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8021898</ArticleId><ArticleId IdType="pubmed">33833683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>